Loading clinical trials...
Loading clinical trials...
A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies
Conditions
Interventions
FS120
Locations
9
United States
Yale University
New Haven, Connecticut, United States
MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
NEXT Oncology, Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Start Date
November 18, 2020
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2026
Last Updated
June 27, 2025
NCT04657068
NCT04585750
NCT07197671
NCT05831579
NCT04900818
NCT05004116
Lead Sponsor
invoX Pharma Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions